Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer's Disease by Pickett, Eleanor K. et al.
                                                                    
University of Dundee
Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional
Deficits in a Model of Alzheimer's Disease









Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Pickett, E. K., Herrmann, A. G., McQueen, J., Abt, K., Dando, O., Tulloch, J., ... Spires-Jones, T. L. (2019).
Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of
Alzheimer's Disease. Cell Reports, 29(11), 3592-3604.e5. https://doi.org/10.1016/j.celrep.2019.11.044
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 24. Dec. 2019
ArticleAmyloid Beta and Tau Cooperate to Cause
Reversible Behavioral and Transcriptional Deficits in
a Model of Alzheimer’s DiseaseGraphical AbstractHighlightsd Ab and tau work together to cause behavioral and
transcriptional deficits in mice
d In mice with Ab and tau, glial gene expression increases and
synaptic genes decrease
d Tau is present in synaptic terminals in APP/PS1+Tau mice
and human Alzheimer brain
d In mice, lowering tau levels improves cognition and restores
gene expressionPickett et al., 2019, Cell Reports 29, 3592–3604
December 10, 2019 ª 2019 The Author(s).
https://doi.org/10.1016/j.celrep.2019.11.044Authors








One of the mysteries of Alzheimer’s
disease is how the two key pathological
proteins, amyloid beta and tau, interact.
Pickett et al. use a mouse model to show
that these proteins cooperate to change
behavior and gene expression and that
these phenotypes recover when tau
levels are lowered.
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A key knowledge gap blocking development of effec-
tive therapeutics for Alzheimer’s disease (AD) is the
lack of understanding of how amyloid beta (Ab) pep-
tide and pathological forms of the tau protein coop-
erate in causing disease phenotypes.Within amouse
tau-deficient background, we probed the molecular,
cellular, and behavioral disruption triggered by the
influence of wild-type human tau on human Ab-in-
duced pathology.We find that Ab and tauwork coop-
eratively to cause a hyperactivity behavioral pheno-
type and to cause downregulation of transcription
of genes involved in synaptic function. In both our
mouse model and human postmortem tissue, we
observe accumulation of pathological tau in synap-
ses, supporting the potential importance of synaptic
tau. Importantly, tau reduction in the mice initiated
after behavioral deficits emerge corrects behavioral
deficits, reduces synaptic tau levels, and substan-
tially reverses transcriptional perturbations, sug-
gesting that lowering synaptic tau levels may be
beneficial in AD.
INTRODUCTION
More than 50 million people are living with dementia today, and
approximately $800 billion per year is spent worldwide on their
health and social care (Prince et al., 2015). Alzheimer’s disease
(AD) is the most common cause of dementia, and current treat-
ments are only minimally effective and do not prevent brain
degeneration or cognitive decline. AD is defined pathologically3592 Cell Reports 29, 3592–3604, December 10, 2019 ª 2019 The A
This is an open access article under the CC BY license (http://creativeby the accumulation of amyloid plaques made of aggregated
amyloid beta (Ab), neurofibrillary tangles that are intraneuronal
deposits of hyperphosphorylated tau protein, and brain atrophy
because of neuron and synapse loss. The predominating hy-
pothesis in the AD field, the amyloid cascade hypothesis, posits
that changes in Ab initiate a cascade of events, including patho-
logical changes in tau (Hardy and Higgins, 1992; Hyman, 2011).
Genetic studies indicate that changes in the innate immune sys-
tem are also important in conferring disease risk (De Strooper
and Karran, 2016; Henstridge et al., 2019). How Ab, glial, innate
immune changes, and tau interact to cause neurodegeneration
remains a key knowledge gap in the field.
Synapses are important targets to study in AD, because syn-
apse degeneration is the strongest correlate of cognitive decline
(Terry et al., 1991) and synapses are important early in disease
pathogenesis and the spread of pathological proteins through
the brain (Spires-Jones and Hyman, 2014; Spires-Jones et al.,
2017; DeVos et al., 2018b). Substantial amounts of evidence
implicate oligomeric Ab in synapse degeneration in model sys-
tems and in human postmortem tissue (Li et al., 2009; Mucke
and Selkoe, 2012; Klein, 2013; Spires et al., 2005; Spires-Jones
et al., 2007, 2009; Koffie et al., 2009, 2012; Jackson et al., 2019).
Some toxic effects of Ab appear to be mediated by cascades
that are normally involved in the innate immune system, including
complement and TREM2 (Hong et al., 2016; Jay et al., 2017; Yeh
et al., 2016; Henstridge et al., 2019). Pathological forms of tau are
also sufficient to induce synapse loss and circuit dysfunction in
models of tauopathy (Kopeikina et al., 2012; Menkes-Caspi
et al., 2015; Crimins et al., 2013; Fox et al., 2011; Hoover et al.,
2010; Zhou et al., 2017; Busche et al., 2019).
There is accumulating evidence that Ab and tau may act syner-
gistically to cause synaptic dysfunction, neurofibrillary tangle-
mediated neuron loss, and behavioral deficits (Ittner et al., 2010;
Vargas-Caballero et al., 2017; Roberson et al., 2011; Shiptonuthor(s).
commons.org/licenses/by/4.0/).
Figure 1. Progressive Plaque Pathology without Tau Pathology in APP/PS1+Tau Mice
(A) APP/PS1+Tau mouse model was generated by breeding two feeder lines to produce four experimental genotypes of F1 littermates on a consistent outbred
strain background.
(B) Behavior, pathology, and recovery with tau transgene suppression were characterized over time.
(C and D) Staining with thioflavin S (C) shows progressive plaque accumulation in APP/PS1+Tau and APP/PS1 mice. APP/PS1+Taumice have significantly lower
cortical plaque burden than APP/PS1 mice (D, two-way ANOVA, effect of genotype F[2,26] = 8.454, p = 0.007).
(E) Tau is present in 14.5-month-old APP/PS1+Tau mice as shown with a total tau stain, but tau pathology does not accumulate in cell bodies or in dystrophic
neurites around plaques, as shown by staining with phospho-tau (PHF1 and AT8) or misfolded tau (Alz50) antibodies, which all label tangle pathology in rTg4510-
positive control sections.
(F) None of the genotypes experienced age-related cortical atrophy (two-way ANOVA, effect of age, p > 0.05).
Data shown are means ± SE. Dots on bar graphs represent means of individual animals (n per group, biological replicates, shown in each bar). Scale bars
represent 1 mm (C, insets 100 3 100 mm) and 30 mm (E). See also Figure S1 and Table S1.et al., 2011; Jackson et al., 2016; DeVos et al., 2018a). However,
much previouswork was confounded by the complex differences
between mouse and human tau and the inability to control tau
expression. Furthermore, many previous studies examining inter-
actions between Ab and tau used tau mutations associated with
frontotemporal dementia to drive neurofibrillary pathology.
Although these are excellent models for studying tau pathology,
they do not accurately recapitulate the state in early AD in which
soluble, wild-type human tau is likely interacting with rising levels
of oligomeric Ab to confer synaptic toxicity. To overcome these
limitations, and to test the hypothesis that Ab and tau act cooper-
atively to cause behavioral and transcriptional deficits, we de-
signed a model lacking endogenous mouse tau (MAPTnull) and
expressingboth theAPP/PS1 transgene,whichcauseswell-char-
acterized plaque-associated synapse loss (Jankowsky et al.,
2004; Koffie et al., 2009), and the rTg21221 line that reversibly ex-
presseswild-typehuman tauunder thecontrol of an induciblepro-
moter (Hoover et al., 2010). This MAPTnull+APP/PS1+rTg21221
AD model (APP/PS1+Tau) allows control over tau levels by sup-
pression of tau transgene expression.We examined the behavior,
pathology, synapse degeneration, transcriptional changes, and
accumulation of Ab and tau at synapses in the APP/PS1+Tau
model and compared these data to observations of synapses in
human postmortem brain using the high-resolution array tomog-
raphy imaging technique (Kay et al., 2013).RESULTS
APP/PS1+Tau Mice Develop Age-Related Behavioral
and Transcriptional Phenotypes
To understand the effects of combining plaque pathology with
human tau expression, we examined pathology and behavior
during aging in APP/PS1+Tau mice and 3 littermate control ge-
notypes: control (MAPTnull), APP/PS1 only (MAPTnullxAPP/
PS1), and human tau only (MAPTnullxrTg21221) (Figures 1A
and 1B). Pathological and behavioral data for each mouse are
found in Table S1. APP/PS1+Tau mice develop progressive am-
yloid plaque pathology in the absence of tau pathology (Figures
1C–1E). Similar to previous data for the rTg21221 line (Hoover
et al., 2010), APP/PS1+Tau mice overexpress human tau 12-
fold compared with endogenous mouse tau levels seen in wild-
type mice by qPCR (human and mouse tau normalized to
GAPDH, n = 5 per group, data not shown). In both genotypes
of mice expressing the APP/PS1 transgene, amyloid plaques
begin to appear in cortex and hippocampus by 6 months of
age and plaque burden increases with age. Plaque deposition
differs between APP/PS1 mice and APP/PS1+Tau mice, with
surprisingly lower plaque in APP/PS1+Tau mice (Figure 1D).
Although human tau mRNA and protein could be detected in
the two genotypes expressing both the human tau responder
gene and the CkTta activator transgene, no tau pathology wasCell Reports 29, 3592–3604, December 10, 2019 3593
Figure 2. Hyperactivity and Transcriptional Changes in APP/PS1+Tau Mice
(A and B) Open-field test was used as a measure of spontaneous activity. Representative traces from a mouse from each genotype at 10.5 months of age (A),
demonstrate the excess activity of the APP/PS1+Tau mice compared with the other three genotypes (B, two-way ANOVA, effect of genotype F[3,202] = 314.76,
p = 0 < 0.0001; *Tukey’s post hoc tests, p% 0.01, all comparisons of APP/PS1+Tau versus other 3 genotypes at 10.5 and 14.5 months; n of mice as biological
replicates per group are noted on the graph). The dotted line in (B) indicates different cohorts of mice was used at 3, 6, and 9months and at 10.5 and 14.5 months.
(legend continued on next page)
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observed at any age with staining for phosphorylated or mis-
folded tau epitopes (AT8, PHF1, or Alz50) or with histological
staining of fibrils with thioflavin S (ThioS) (Figure 1E). The efficacy
of tau staining was confirmed using rTg4510 mouse brain sec-
tions (which express a form of tau associated with frontotempo-
ral dementia and contain tangle pathology), verifying that all tau
antibodies stained neurofibrillary tangles. APP/PS1+Tau mice
did not exhibit age-related atrophy in cortex (Figure 1F) or hippo-
campus (Figure S1).
In addition to plaque accumulation and human tau expression,
APP/PS1+Tau mice exhibit an age-related hyperactivity pheno-
type (Figures 2A and 2B). After 3 days of habituation, mice were
placed in an open field and the total distance traveled over
10 min was recorded. Two-way ANOVA reveals a significant ef-
fect of genotype (F[3,202] = 314.76, p < 0.0001), with APP/
PS1+Tau mice traveling farther than controls at 10.5 and
14.5 months of age (Tukey’s multiple comparison test, p %
0.01, for all comparisons of APP/PS1+Tau versus the other 3 ge-
notypes at 10.5 and 14.5 months). There was no effect of age
when all mice were considered together (F[4,202] = 1.61,
p = 0.17), but there was a significant interaction between age
and genotype (F[12,202] = 2.30, p = 0.01), because the APP/
PS1+Tau mice travel farther in the open field than the other ge-
notypes as they age. The hyperactivity phenotype is not different
in male versus female APP/PS1+Tau mice (Figure S2). Neither is
the hyperactivity driven by tau protein levels that do not differ be-
tween APP/PS1+Tau mice and tau mice as measured by ELISA
in cortical homogenates from 14.5-month-old mice (mean:
11.0 ng/mg of total protein in tau mice, 9.5 ng/mg of total protein
in APP/PS1+Tau mice; n = 5 per group, p > 0.05, Tukey’s post
hoc test). Group sizes and sex of mice in behavioral studies
are shown in figures and in Table S1.
To examine transcriptional changes in APP/PS1+Taumice, we
performed unbiased RNA sequencing (RNA-seq) on brain ho-
mogenates at 14.5 months of age (RNA-seq data are found in
Table S2). When compared with control mice, APP/PS1 had 81
transcripts that changed more than 2-fold and had an adjusted
pvalue of less than0.05 (Figure 2C). Taumicewere similar to con-
trols, with only 6 transcripts significantly changing more than(C) RNA-seq of APP/PS1 brain compared with controls reveals significant chang
mapped reads, biological replicates were mice, n = 5 per group).
(D) Wild-type human tau induced changes to a lesser extent.
(E) APP/PS1+Tau mice had more significant changes than when either APP/PS1
(F) Examining only the genes significantly changed in APP/PS1+Tau mice compa
the x axis to the maximum L2FC of either APP/PS1 or Tau compared with con
regulated in APP/PS1+Taumice compared with those expressing APP/PS1 or tau
to 0.92; dotted red line is x = y, showing expected values if there were no differenc
APP/PS1+Tau mice compared with those expressing APP/PS1 or tau alone (blac
transcripts of interest that are changed more in APP/PS1+Tau mice than in APP/
and upregulated genes involved in inflammation.
(G) Pathway analysis of all RNA-seq data reveals that many upregulated pathw
downregulated pathways are also downregulated in Tau mice (orange indicates i
from Ingenuity Pathway Analysis software). However, some pathways changed
creases in the complement system and decreases in glutamatergic signaling.
(H) Confocal imaging of Iba1 and synaptophysin staining shows that microglia e
physin inside microglia). Scale bar shows 5 microns.
Transcripts that changed more than 2-fold with adjusted p < 0.05 are shown in red
gene names. Each cross in (C)–(F) represents the average value of 5 mice per gen
and Tables S1, S2, and S3.2-fold, 1 of which isMapt, which is expected due to tau overex-
pression (Figure 2D). In contrast, APP/PS1+Tau mice had 1,531
transcripts that were significantly altered compared with
MAPTnull controlmice and 127of thesewere changedby greater
than 2-fold (Figure 2E). Thus, the gene changes in APP/PS1+Tau
mice compared with control are larger than either APP/PS1mice
or Tau mice, indicating cooperation between Ab and tau in
causing transcriptional dysregulation. Ingenuity Pathway Anal-
ysis indicates that many upregulated genes in APP/PS1+Tau
mice are typically expressed in glia (summary pathways of inter-
est based on the literature are shown in Figure 2G; full pathway
analyses are in Table S3). This includes increased expression of
Trem2, Gfap, Cd68, C1q, and H2-Eb1 and significant increases
in canonical pathways implicated in neuroinflammation (Fig-
ure 2G). Many downregulated genes in APP/PS1+Tau mice are
involved in canonical pathways involved in synaptic function,
including glutamate receptor signaling and calcium signaling
(AMPA andNMDA receptor subunits;Gria2,Gria3,Gria4,Grin2a,
Homer2, and Camk2b are downregulated) (Figure 2G). One syn-
aptic transcript that was significantly upregulated is cellular prion
protein (Prnp), which is interesting, because it is a knownsynaptic
binding partner of Ab (Um et al., 2012).
Upregulation of genes in APP/PS1+Tau mice appears to be
largely driven by Ab and tau independently without an additive
effect, because the fold induction of upregulated genes is similar
in APP/PS1+Tau mice to the maximum fold induction in either
APP/PS1 or Tau mice. Most upregulated transcripts in APP/
PS1+Tau mice correlate strongly with the maximum fold change
in APP/PS1 mice (Figure 2F), and most upregulated pathways in
APP/PS1+Tau mice are upregulated to a similar extent in APP/
PS1 mice (Figure 2G). There are a few pathways upregulated
more in APP/PS1+Tau mice than in APP/PS1 or Tau mice,
including the complement system (Figure 2G). In contrast to
the relatively few changes seen in upregulated genes, Ab and
tau act additively in downregulating gene expression. The fold
downregulation compared with controls in APP/PS1+Tau
mice is more than the maximum change in either APP/PS1
mice or Tau mice (Figure 2F). Interestingly, pathway analysis re-
veals the glutamate receptor signaling pathway is significantlyes in gene expression (FPKM, fragments per kilobase of transcript per million
or Tau were expressed on their own.
red with control mice, and comparing the log(2) fold change (L2FC) of these on
trols on the y axis shows that upregulated genes are mostly not differentially
alone (black line linear regression slope, 0.9; 95% confidence interval [CI], 0.89
es). Downregulated genes in APP/PS1+Tau mice are differentially regulated in
k line linear regression slope, 0.57; 95% CI, 0.51 to 0.63). Green crosses show
PS1 or Tau mice, including downregulated genes involved in synaptic function
ays in APP/PS1+Tau mice are also upregulated in APP/PS1 mice and most
ncreases, and blue indicates decreases compared with control levels; analysis
more in the APP/PS1+Tau line compared with the parent lines, including in-
ngulf synaptic proteins around plaques (arrows show localization of synapto-
in (C)–(E). A few transcripts of interest based on previous work are labeled with
otype of a single transcript detected at a value of >1 FPKM. See also Figure S2
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Figure 3. Lowering Tau Levels Ameliorates Hyperactivity Phenotype and Transcriptional Changes
(A) Transgene suppression (dox) reduced human tau mRNA levels by approximately 65% as measured by qPCR (*two-way ANOVA, effect of treatment F[1,31] =
42.22, p < 0.0001).
(B and C) Representative traces of open-field activity from a APP/PS1+Tau mouse treated with vehicle and one treated with doxycycline, and the trace from the
same mice after treatment (B), show clear amelioration of hyperactivity phenotype in one mouse, which is confirmed by quantification of distance traveled
(C, repeated-measures ANOVA, effect of genotype F[3,69] = 34.12, p < 0.0001; effect of treatment F[1,69] = 6.75, p = 0.01; interaction F[3,69] = 6.13, p = 0.001;
*Tukey’s multiple comparison tests, dox-treated APP/PS1+Tau mice are significantly different from vehicle-treated APP/PS1+Tau mice at 14.5 months of age,
p < 0.0001).
(D) RNA-seq data show that dox treatment to reduce tau levels reverses transcriptional changes in APP/PS1+Tau mice (linear regression slope = 0.34, 95%
CI 0.36 to 0.33). Each point represents a single transcript (average of n = 5 mice per group).
(E) Pathway analysis reveals that the top 15 up- and downregulated canonical pathways in APP/PS1+Taumice comparedwith controls recover to normal levels or
past normal levels with dox treatment (orange indicates increases, and blue indicates decreases compared with control levels; analysis from Ingenuity Pathway
Analysis software).
Biological replicate/experimental unit for each experiment is an individual mouse, n per group shown in (A) and (C). See also Figures S3 and S4 and Tables S1, S2,
and S3.decreased in APP/PS1+Tau mice compared with controls and
unaffected in either parent line (Figure 2G). One potential mech-
anistic link between upregulated inflammatory pathways and
synaptic dysfunction and decreases in synaptic gene expression
is the phagocytosis of synaptic proteins by microglia. The com-
plement system has been previously shown to be involved in
phagocytosis of synapses in plaque- and tangle-bearing models
separately (Dejanovic et al., 2018; Hong et al., 2016; Litvinchuk
et al., 2018; Shi et al., 2017). In addition to upregulation of genes
involved in the complement system and downregulation of
genes involved in synaptic function in APP/PS1+Tau mice, we
observe synaptic phagocytosis by microglia (Figure 2H).
Cooperative Effects of Ab and Tau on Behavior and
Transcription Are Ameliorated by Lowering Tau Levels
in APP/PS1+Tau Mice
To determine whether the phenotypes observed in APP/
PS1+Tau mice could be ameliorated by lowering tau levels, a3596 Cell Reports 29, 3592–3604, December 10, 2019cohort of mice was treated with doxycycline (dox) from 10.5 to
14.5 months to suppress tau transgene expression. Dox treat-
ment lowered tau expression by 65% in APP/PS1+Tau mice
(Figure 3A). Although this lowering of human tau levels was
not complete and remained higher than endogenous mouse
tau levels would be in a wild-type mouse, it ameliorated the hy-
peractivity phenotype in APP/PS1+Tau mice (Figures 3B and
3C). Doxycycline treatment also ameliorates gene expression
changes in APP/PS1+Taumice (Figures 3D and 3E) and reverses
themild changes in Taumice (Figure S3), indicating that lowering
tau levels protects against gene expression changes. Pathway
analysis reveals a striking amelioration of the top 15 most up-
and downregulated networks in APP/PS1+Tau mice treated
with dox (Figure 3E).
To test whether the recovery of gene expression with tau sup-
pression resulted from prevention of further changes with age or
a recovery of existing changes at the time treatment began, we
analyzed a subset of transcripts by RT-PCR at 9–10 months of
age (an age before treatment started) and validated the RNA-seq
data with RT-PCR in 14.5-month-old brain samples that had
been treated with vehicle or dox. The subset of genes tested
indicate that the amelioration of gene expression changes with
dox resulted from prevention of further worsening, not recovery
(Figure S3). Because many upregulated inflammatory genes are
expressed in glia, we examined astrocyte and microglial bur-
dens. In agreement with the RNA-seq observation that upregu-
lated genes are driven largely by Ab without an additive effect
of tau, an increase in gliosis was observed in both genotypes
with human Ab (APP/PS1+Tau and APP/PS1 mice). The burden
of gliosis did not recover with dox treatment; however, many in-
flammatory markers expressed by glia were reduced with tau
suppression, which may contribute indirectly to the recovery of
the levels of synaptic genes involved in glutamatergic signaling
(Figure 3E). In particular, the increases in transcripts involved in
the complement system are normalized by dox treatment (Fig-
ure S3), which is of interest due to the recent links between com-
plement and pruning of synapses in mice expressing frontotem-
poral dementia associated mutant tau (Dejanovic et al., 2018;
Litvinchuk et al., 2018).
To examine whether the increased distance traveled by APP/
PS1+Tau mice resulted from anxiety, we examined the distance
traveled in the inner versus theouter portions of thearena.Miceof
all genotypes spend approximately 10 times more time in the
outer than the inner arena, indicating a typical avoidance of
open areas (Figure S2). At 14.5 months of age (after treatment),
there was no significant effect of genotype or treatment on dis-
tance traveled in the inner arena (two-way ANOVA, genotype
F[3,69] = 1.854, treatment F[1,76] = 0.204, interaction F[2,69] =
0.153, p > 0.05). In the outer arena, there were significant effects
of genotype, treatment, and an interaction between genotype
and treatment on distance traveled. APP/PS1+Tau vehicle-
treated mice traveled significantly farther in the outer arena
thanall other groups. This indicates apotential anxiety phenotype
and hyperactivity, which recovers with doxycycline treatment.
Tau in Synapses May Mediate Behavioral and
Transcriptional Changes
To examine the brain changes underpinning the recovery of
behavior with tau suppression, postmortem studies of patholog-
ical and molecular changes were carried out in the cohort of
mice that had undergone treatment. Amyloid plaque pathology
is unchanged with tau suppression (Figure S4). The ThioS plaque
burden, cross-sectional area of individual ThioS-stained plaques,
AW7-immunostained plaques (which label both the dense core
and theoligomerichalo surrounding thecore), andareaof theolig-
omeric Ab halo surrounding plaqueswere all unchangedwith dox
treatment. Expression of APPmeasured by qPCRwas increased
in APP/PS1+Tau mice compared with APP/PS1 littermates and
this increasewas ameliorated by tau transgene suppression. Sol-
uble levels of Ab 42 peptide, however, were not different in APP/
PS1+Taumice comparedwithAPP/PS1mice, andalthough there
wasa significant effect of treatment across groups, post hoc tests
show no difference between APP/PS1+Tau vehicle- and dox-
treated mice in Ab 42 levels (Figure S4). These data indicate that
the behavioral and gene transcription recovery was not mediated
by reducing amyloid pathology.Synapse density around plaques and the accumulation of syn-
aptic Ab and tauwere determined in entorhinal cortex using array
tomography. More than 673,000 postsynaptic densities labeled
with PSD95 and 415,000 presynaptic terminals labeled with syn-
aptophysin were analyzed from cortical samples from 4 to 11
mice per group (average 13,000 PSDs and 9,655 presynaptic
puncta per mouse). The density of both synaptophysin (Figure 4)
and PSD95 (Figure S5) labeled puncta decreased near plaques
in the two genotypes that have plaques (APP/PS1 and APP/
PS1+Tau mice, three-way ANOVA, effect of plaque distance
synaptophysin F[1,42] = 60.49, p < 0.0001; PSD95 F[1,50] =
8.15, p = 0.006). Treatment with doxycycline to reduce tau levels
did not prevent this plaque-associated synapse loss. The density
of pre- and postsynapses near plaques was not significantly
different between treatment groups or genotypes. Oligomeric
Ab accumulated in a subset of synapses near plaques in both
APP/PS1 and APP/PS1+Tau mice (median presynaptic termi-
nals near plaques containing Ab, 1.9% in APP/PS1 mice and
0.8% in APP/PS1+Tau mice; median postsynaptic terminals,
1.0% in APP/PS1 mice and 2.4% in APP/PS1+Tau mice). The
percentage of both pre- and postsynaptic terminals containing
Abwas higher near plaques in both APP/PS1 and APP/PS1+Tau
mice (independent samples, Mann-Whitney U test, PSD95, p <
0.01; synaptophysin, p < 0.0001, for all groups near versus far
from plaques). The percentage of synapses containing Ab near
plaques was not different between APP/PS1 and APP/PS1+Tau
mice (independent samples, Mann-Whitney U test, p > 0.05).
There was also no effect of lowering tau levels on accumulation
of Ab in synapses near plaques (independent samples, effect of
treatment, Mann-Whitney U test, p > 0.05).
Tau was detected in the median of 0.4% of presynapses (Fig-
ure 4E) and 1.2% of PSDs (Figure S5) in vehicle-treated APP/
PS1+Tau mice and 1.1% of presynapses and 0.6% of PSDs in
vehicle-treated Tau mice. Tau was not detected in synapses in
mice that did not express tau (control and APP/PS1). Unlike
Ab, the percentage of synapses containing tau was not different
near plaques in the APP/PS1+Tau group. The percentage of syn-
apses containing tau was significantly different between geno-
types (independent samples, Mann-Whitney U test for genotype,
p < 0.0001). Doxycycline treatment significantly lowered synap-
tic tau levels only in the APP/PS1+Tau group (data split by geno-
type, effect of treatment, independent samples, Mann-Whitney
U test, p = 0.004 for PSD95, p = 0.004 for synaptophysin). The
approximate 30-fold reduction in presynaptic tau levels and
8-fold reduction in postsynaptic tau levels in APP/PS1+Tau
mice may contribute to the improved hyperactivity phenotype
and ameliorated transcriptional profiles observed in mice treated
with doxycycline. However, this will need to be confirmed in
future studies, because treatment lowered tau levels globally,
not just in synapses. Only rare PSDs stained for both Ab and
tau (<0.006% of presynapses and <0.005% of postsynapses in
vehicle-treated APP/PS1+Tau mice).
Tau Is Present in Pre- and Postsynapses of Human AD
Cases
To confirm the translational relevance of the contribution of syn-
aptic tau to cognitive decline in our model, we examined the
localization of tau and Ab at synapses in samples of superiorCell Reports 29, 3592–3604, December 10, 2019 3597
Figure 4. Tau Suppression Reduces Presynaptic Accumulation of Tau in the Entorhinal Cortex
To investigate synapse loss and synaptic proteins, array tomography ribbons from 14.5-month-old mice were stained for presynaptic terminals (synaptophysin,
green) human tau (red), and amyloid beta (AW7, cyan).
(A) Maximum intensity projections of 10 serial 70-nm sections of a mouse in each group are shown.
(B) Three-dimensional reconstructions of 5 consecutive serial sections from processed image stacks of a APP/PS1+Tau mouse demonstrate presynaptic ter-
minals positive for tau (arrows) or Ab (arrowheads).
(C) Quantification reveals significant presynaptic loss near plaques in APP/PS1 and APP/PS1+Tau mice, which is not rescued by lowering tau levels with
doxycycline (dox) treatment.
(D) Percentage of presynapses positive for Ab is not different betweenMAPTnullxAPP/PS1mice and APP/PS1+Tau mice, and it is not affected by dox treatment.
(E) Percentage of presynapses containing tau is significantly lowered by dox treatment in APP/PS1+Tau mice (*Mann-Whitney U test, p = 0.004).
Data represent mean + SEM (C) and median + interquartile range (D and E). Scale bars represent 10 mm in (A) and 1 mm in (B). Each dot on the graphs represents the
mean (C) or median (D and E) of a single mouse (biological replicate/experimental unit = mouse, n shown in each panel). See also Figures S4 and S5 and Table S1.temporal gyrus from human subjects. In total, 99,967 postsynap-
ses and 100,012 presynapses from 6 AD and 6 control subjects
were examined (mean: 8,331 postsynapses and 8,334 presy-3598 Cell Reports 29, 3592–3604, December 10, 2019napses examined per case, data found in Tables 1 and S4).
Cases were stained with the pan-Ab antibody AW7, a total tau
antibody, a presynaptic marker, and a postsynaptic marker in
Table 1. Human Subject Characteristics
Case Diagnosis Age (Year) Sex
1442 AD 80 f
1446 AD 84 m
1547 AD 77 m
1564 AD 90 m
AD5 AD 75 f
BBN24526 AD 79 m
HC control 66 m
HC2 control 69 m
HC3 control 75 m
HC6 control 95 m
BBN28406 control 79 m
BBN19686 control 77 fa two-day protocol to allow localization of Ab and tau, together
within individual pre- and postsynapse. As previously reported,
Ab is present in a subset of synapses in AD brain (Koffie et al.,
2012; Jackson et al., 2019). In this cohort, we again observe
significantly more positive synapses within 20 mm of a plaque
(median: 10.4% PSD and 8.0% synaptophysin puncta positive
for Ab near plaques and <1% PSD or synaptophysin positive
for Ab far from plaques, p < 0.05; independent samples, Mann-
Whitney U test for both pre- and postsynapses). In array tomog-
raphy, the tau13 antibody recognized neurofibrillary pathology,
but not normal axonal tau, and labeled a small subset of pre-
and postsynapses (Figure 5). As observed in the mice, tau syn-
aptic localization was not different near versus far from plaques.
Also in agreement with the mouse data, only rare synapses were
positive for both tau and Ab staining (<0.02% on average). Mis-
folded and phosphorylated tau were also detected in human
synapses using array tomography staining with Alz50, MC1,
and CP13 antibodies (Figures 5G–5J; Table 2).
DISCUSSION
The lack of disease-modifying treatments for AD remains a huge
unmet clinical need. Synapse degeneration is the strongest
pathological correlate of cognitive decline in AD and a potentially
important driver of disease pathogenesis. Previous work by our
group and others strongly implicated soluble Ab and tau sepa-
rately in synapse dysfunction and loss in AD (Spires-Jones and
Hyman, 2014; Klein, 2013; Koffie et al., 2009, 2012; Kopeikina
et al., 2012; Mucke and Selkoe, 2012; Spires-Jones et al.,
2017). Here we tested the hypothesis that Ab and tau act
together to cause neural circuit dysfunction. Evidence has
been growing to support this idea from work showing that
lowering tau levels protects against Ab-mediated synaptic plas-
ticity deficits, from studies indicating that dendritic tau mediates
Ab synaptotoxicity, and from a study that found synaptic tau
phosphorylation in APP/PS1 mice (Roberson et al., 2007,
2011; Shipton et al., 2011; Ittner et al., 2010; Zempel et al.,
2010; Wu et al., 2018). Recent work in a mouse model express-
ing both APP/PS1 and P301L mutant tau, which is associated
with frontotemporal dementia, showed that reducing levels ofmutant tau prevents neuronal loss (DeVos et al., 2018a). In our
APP/PS1+Tau model, the tau expressed is wild-type human
tau without endogenous mouse tau, making this relevant to early
Alzheimer’s disease.
In this APP/PS1+Tau model, we observe an age-related hy-
peractivity phenotype and downregulation of genes involved in
synaptic function. Pathologically, we observe tau in both pre-
and postsynapses in human brain and in our APP/PS1+Tau
model. Tau was rarely colocalized with Ab within individual syn-
apses. Reducing tau expression levels ameliorated the behav-
ioral and gene expression phenotypes and lowered synaptic
tau levels without recovering synapse density around plaques.
Importantly, doxycycline treatment of our mice did not
completely remove human tau, indicating that a partial reduction
in tau levels may be sufficient in humans to allow some functional
recovery. This may be more achievable than complete knock-
down and could preserve physiological functions of tau. Alto-
gether, these data support the hypothesis that Ab and tau act
together to cause synapse dysfunction. However, this interac-
tion likely does not likely result from physical colocalization of
small aggregates of these pathological proteins within the
same synapses, at least within the limits of our detection.
We surprisingly observed that human tau expression in the
absence of mouse tau resulted in smaller plaques in APP/
PS1+Tau mice, whereas we previously saw that adding human
tau with the same transgenic line when endogenous mouse tau
is still present resulted in slightly larger plaques (Jackson et al.,
2016). This implies that either mouse and human tau function
differently in mouse brain, that the overexpression of human
tau results in effects different from those of endogenous levels
of mouse tau, or that the temporal and spatial expression pattern
driven by the Ca2+/calmodulin-dependent protein kinase type II
subunit alpha (CaMKIIa) promoter does not recapitulate accu-
rately the physiological expression of endogenous tau. Alto-
gether, these data highlight the importance of examiningmultiple
models, including knockin lines (Sasaguri et al., 2017), and of us-
ing human postmortem tissue, as well as mouse models, to
ensure the translatability of findings.
Potential molecular mechanisms linking Ab and tau to synapse
and circuit dysfunction include calcium dysregulation and calci-
neurin activation, which are known to contribute to Ab toxicity
and spine collapse in vitro and in vivo and have been linked to
tau-mediated synapse impairment (Wu et al., 2010; Hudry
et al., 2012; Kuchibhotla et al., 2008; Mattson et al., 1992; Zem-
pel et al., 2010; Yin et al., 2016). Human tau expression causes
circuit hypoactivity, even in APP/PS1 mice, which usually exhibit
hyperactive neurons (Busche et al., 2019). These data are in line
with our current study, because both show cooperativity be-
tween Ab and tau in impairing neuronal activity and circuit
function.
Abnormal activation of synaptic receptors by Ab has also
been shown to induce activation of kinases, including Fyn and
GSK3-b, which affect tau phosphorylation and synapse collapse
(Purro et al., 2012; Lovestone et al., 2014; Small and Duff, 2008;
Marzo et al., 2016; Sellers et al., 2018; Ittner et al., 2010; Rober-
son et al., 2011). Our RNA-seq results add to the literature impli-
cating cellular prion protein at the interface between Ab and tau,
because increases in PrPc mRNA in APP/PS1+Tau mice wereCell Reports 29, 3592–3604, December 10, 2019 3599
Figure 5. Tau Is Found in Pre- and Postsynapses in Human AD Brain
(A–F) Array tomography was used in human AD and control postmortem brain tissue to stain Ab (white), Tau13 (yellow), PSD95 (magenta), and synaptophysin
(cyan). Tau13 stains neuropil threads (A, arrows). Examining individual synapses revealed that Ab was present in 8.0% of presynaptic terminals (B, arrowheads)
and 10.4% of postsynaptic densities (B, arrows) near plaques in AD cases (B and E). Tau13 staining was observed in 0.23% of presynaptic terminals (C, ar-
rowheads, quantified in F), and 0.32% of postsynaptic terminals (D, arrows, quantified in F).
(G–I) Misfolded tau labeled with Alz50 (yellow) was observed in neuropil threads (G, arrows) and in presynapses (H, arrowheads) and postsynapses (I, arrows).
(J) Tau phosphorylated at serine 202 (labeled with CP13) and misfolded (residues 5–15 near 312–322, labeled with MC1) was observed in PSDs.
Images in (A) and (G) and large panels in (J) are maximum intensity projections of 10 serial sections. Scale bar represents 10 mm in (A), (G), and (J). (B)–(D), (H), (I),
and insets in (J) show three-dimensional reconstructions of a 23 2 micron region of interest in 5 consecutive serial 70-nm sections. Data shown are median and
interquartile ranges. Each dot represents the median of a single human subject (subject is the biological replicate/experimental unit, n = 6 per group). See also
Table S4.the largest change observed with RNA-seq and these levels
recover with tau suppression. PrPc has been shown to interact
with oligomeric Ab, where it is thought to act via metabotropic
glutamate receptor 5 complexes to impair synaptic function
(Haas and Strittmatter, 2016; Jarosz-Griffiths et al., 2016; Barry
et al., 2011; Hu et al., 2014, 2018). This pathway could involve
tau, because binding of Ab to PrPc can activate Fyn and cause
tau phosphorylation (Um et al., 2012, 2013). Although many pro-
posed mechanisms of synapse degeneration focus on postsyn-
aptic processes, our data clearly show accumulation of both Ab
and tau in pre- and postsynaptic terminals. Tau has been shown
to bind to presynaptic vesicles in human AD and Drosophila
models, where it impairs neurotransmitter release (Zhou et al.,
2017; McInnes et al., 2018). Similarly, it is becoming clear that
Ab exerts effects on presynaptic function (Ovsepian et al., 2018).
Our RNA-seq results strongly implicate non-neuronal cells as
key participants in the interplay between Ab and tau, which is
of interest in the field (Henstridge et al., 2019). TREM2, clusterin,
and CD33, genes involved in the innate immune system that
have been implicated in AD risk by genome-wide association
studies (GWASs), were elevated in APP/PS1+Tau mice com-
pared with controls. Several members of the complement
cascade family were also changed in APP/PS1+Tau mice, which
is important due to the discovery of complement-mediated mi-
croglial engulfment of synapses in plaque-bearing AD model3600 Cell Reports 29, 3592–3604, December 10, 2019mice (Hong et al., 2016; Shi et al., 2017). Previous data on tran-
scriptional changes in amyloid models compared with tau
models demonstrated that changes in immune gene expression
correlated positively with amyloid pathology and decreases in
synaptic gene expression correlated with neurofibrillary tangle
pathology (Matarin et al., 2015). Our data indicate that beyond
contributing to disease risk, presumably through amyloid, the
innate immune system is also likely involved in the cascade
from amyloid to tau in AD pathogenesis. The gene changes
observed in our model indicate that Ab and tau act cooperatively
to cause downregulation of genes and largely independently in
gene upregulation. Downregulated genes were predominantly
involved in excitatory synaptic function, which is supported by
recent data implicating tau in toxicity to excitatory over inhibitory
neurons (Fu et al., 2017).
We propose that the inflammatory milieu initiated by amyloid
primes the system, making synapses vulnerable to tau-associ-
ated molecular changes such as loss of synaptic proteins. In
the absence of amyloid pathology, our tau-expressing mice do
not develop loss of synaptic protein expression or behavioral ab-
normalities despite accumulation of tau in synapses, whereas
APP/PS1+Taumice have synaptic tau in the context of an inflam-
matory reaction to Ab, which could drive behavioral phenotypes
and loss of synaptic proteins. Recent work in mice expressing
dementia-associated mutant tau indicates that the complement
Table 2. Antibodies Used in Array Tomography and Histology Studies
Primary Antibody Species Source (Cat No.) Dilution Secondary Antibody
Mouse Pathology Study for Amyloid Burden and Cortical and Hippocampal Volumes
AW7 Rb D. Walsh 1:5,000 donkey anti-rabbit Alexa 594, Invitrogen
Mouse Tau Pathology Study (Independent Stains)
PHF1 Ms P. Davies 1:1,000 donkey anti-mouse Alexa 594, Invitrogen
Alz50 Ms IgM P. Davies 1:1,000 donkey anti-mouse IgM Alexa 594, Invitrogen
AT8 Ms Thermo Fisher Scientific (MN1020) 1:1,000 donkey anti-mouse Alexa 594, Invitrogen
Mouse Study of Gliosis Burden
Iba1 Gt Abcam (ab5076) 1:500 donkey anti-goat Alexa 647, Abcam
GFAP Rb Dako (Z0334) 1:2,000 donkey anti-rabbit Alexa 594, Abcam
Mouse Study of Synaptic Proteins inside Microglia
Synaptophysin Ms Abcam (Ab8049) 1:500 donkey anti-mouse Alexa 594, Invitrogen
Iba1 Gt Abcam (ab5076) 1:500 donkey anti-goat Alexa 647, Abcam
Mouse Array Tomography Study of Postsynaptic Density and Protein Colocalization
PSD95 Rb Cell Signal (3450P) 1:50 donkey anti-rabbit Alexa 594, Invitrogen
Tau Gt R&D Systems 1:50 donkey anti-goat Alexa 647, Invitrogen
1C22 Ms D. Walsh 1:500 donkey anti-mouse Alexa 488, Invitrogen
Mouse Array Tomography Study of resynaptic Density and Protein Colocalization
Synaptophysin Ms Abcam (AB8049) 1:50 donkey anti-mouse Alexa 594, Invitrogen
Tau Gt R&D Systems (AF3494) 1:50 donkey anti-goat Alexa 647, Invitrogen
AW7 Rb D. Walsh 1:500 donkey anti-rabbit Alexa 488, Invitrogen
Human Array Tomography Study of Tau13 Synapse Localization Day 1
Synaptophysin Ms Abcam (AB8049) 1:50 donkey anti-mouse Alexa 488, Invitrogen
PSD95 Rb Cell Signal (3450P) 1:50 donkey anti-rabbit Alexa 594, Invitrogen
Human Array Tomography Study of Total Tau Synapse Localization Day 2
Tau13 Ms Covance (MMS-520R) donkey anti-mouse Alexa 488, Invitrogen
AW7 Rb D. Walsh 1:500 donkey anti-rabbit Alexa 594, Invitrogen
IgM, immunoglobulin M. Host species were mouse (Ms), rabbit (Rb), goat (Gt), and guinea pig (Gp).system is involved in neurodegeneration; however, reducing
microglial numbers by inhibiting colony-stimulating factor 1 re-
ceptor (CSF1R) did not ameliorate degenerative phenotypes
(Bennett et al., 2018; Dejanovic et al., 2018; Litvinchuk et al.,
2018). Thus, although mutant tau may be sufficient to induce in-
flammatory phenotypes that contribute to degeneration in mice,
in the context of Alzheimer’s disease, it may be that amyloid in-
duces inflammatory changes that exacerbate degeneration
when tau is present. Our data also suggest that synaptic proteins
may be cleared at least partly by microglial phagocytosis.
Synapses are highly plastic structures that have the potential
for recovery with interventions. Indeed, most successful drugs
used in nervous system disorders act at the synapse; therefore,
synaptic changes are an obvious target for disease-modifying
agents in neurodegenerative disorders. Recent work has
focused on removing Ab from synaptic receptors as a therapeu-
tic avenue. For example, a compound that displaces Ab from
sigma-2 receptors is in clinical trials (Izzo et al., 2014; Grundman
et al., 2019) (https://clinicaltrials.gov/ct2/show/NCT03507790).
Our data indicate that lowering pathological tau or blocking the
inflammatory changes that may link amyloid and tau toxicity
may also be effective therapeutic strategies.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
AW7 antibody, recognizes amyloid beta, polyclonal, raised
in rabbit
provided by Prof Dominic Walsh N/A
PHF1 antibody, recognizes human tau phosphorylated at
Ser396/Ser404, mouse monocolnal IgG1
provided by Prof Peter Davies N/A
Alz50 antibody, recognizes human tau folded to bring amino
acids 2-10 and 312-342 into proximity, mouse IgM
provided by Prof Peter Davies N/A
AT8 antibody, recognizes human tau phosphorylated at
Ser202, Thr205, Mouse monoclonal IgG1
Thermo Fisher RRID:AB_223647
Iba1antibody, Goat polyclonal Abcam RRID:AB_2224402
GFAP antibody, Rabbit polyclonal DAKO RRID:AB_10013382
PSD95 antibody, rabbit monoclonal Cell signaling RRID:AB_2292883
Tau antibody, goat polyclonal R&D Systems RRID:AB_573209
synaptophysin antibody, mouse monoclonal Abcam RRID:AB_2198854




Human Brain Tissue samples Edinburgh Sudden Death Brain
Bank or the Massachusetts General
Hospital Alzheimer’s Disease
Research Centre Brain Bank
Case IDs found in Table 1
Chemicals, Peptides, and Recombinant Proteins
LR White Medium Grade Acrylic Resin Agar Scientific Cat#R1281
Paraformeldahyde 16% Agar Scientific Cat#R1026
Tris buffered saline 10x Fisher BioReagents Cat#BP2471-1
Sucrose Sigma Life Sciences Cat#S0389-1KG
Thioflavin S Fisher Scientific Cat#15537519
Critical Commercial Assays
Tau ELISA Thermo Fisher Scientific Cat#KHB0041
Amyloid beta 1-42 ELISA Thermo Fisher Scientific Cat#KHB3441
Deposited Data
RNA-seq data ArrayExpress E-MTAB-7856





mouse: B6C3-Tg(APPsw,PSEN1dE9)85DboMm Jackson Labs Jax 34829
mouse: FVB.Mapttm1(EGFP)Klt George Carlson, collaborator N/A
mouse: B6.Cg-(Camk2a-tTA)1/MmayDboJ George Carlson, collaborator N/A
mouse: FVB-Tg(tetO-0N4R-MAPTwt)21221 George Carlson, collaborator N/A
Oligonucleotides
See Table S5 N/A
Software and Algorithms
Fiji (ImageJ) v2.0.0 Open Source NIH software N/A
MATLAB v 2018b Mathworks N/A
R package version 2.30.1 r-project free software N/A
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Ingenuity Pathway Analysis v01-14 QIAGEN N/A
Graphpad Prism v7.0d Graphpad N/A
SPSS Statistics v24 IBM N/A
Custom imageJ and MATLAB macros used for image analysis




N/ALEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Prof Tara
Spires-Jones (tara.spires-jones@ed.ac.uk). The newmouse line generated for this project was made using breeding of existing lines
and in some cases material transfer agreements will be needed from the line originators before we can share lines.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All animal experiments conformed to national and institutional guidelines including the Animals [Scientific Procedures Act] 1986 (UK),
and the Council Directive 2010/63EU of the European Parliament and the Council of 22 September 2010 on the protection of animals
used for scientific purposes, and had full HomeOffice ethical approval. Mice were bred in house and group housed in a 12h/12h light/
dark cycle with ad libitum access to food and water. Both sexes of mice were used in all experiments (see Table S1 for details of all
mice used including sex, age, andweight information). Littermates were randomly assigned to experimental groups in experiments to
reduce tau transgene expression and experimenters were blinded to genotype and treatment.
Human subjects
Brain tissue samples were taken from superior temporal gyrus of 6 AD and 6 control subjects in the Edinburgh Sudden Death Brain
Bank or the Massachusetts General Hospital Alzheimer’s Disease Research Centre Brain Bank. Characteristics of human subjects
can be found in Table 1 and synapse data in Table S4. Average agewas 81 for AD cases (range 75-90) and 77 for control cases (range
69-95). All AD caseswere neuropathologically confirmed andwere Braak stage V or VI. Control cases had no neurological phenotype.
All human experiments were reviewed and approved by the Sudden Death Brain Bank ethics committee and the ACCORD medical
research ethics committee (Academic and Clinical Central Office for Research and Development at the University of Edinburgh and
National Health Service Lothian, ethical approval number 15-HV-016).
METHOD DETAILS
Generation of mouse line
For the MAPTnull APP/PS1 rTg21221 (APP/PS1+Tau) model line, 4 genotypes were used to compare mice with (1) no transgene
expression on aMAPTnull background (controls), (2) mice expressing human familial ADmutant APP and PS1 to generate Aß pathol-
ogy (APP/PS1), (3) mice expressing 0N4R wild-type human tau (Tau), and (4) mice expressing both human tau and the APP/PS1
transgene (APP/PS1+Tau, Figure 1). All mice were homozygous for deletion of mouse tau and heterozygous for the human wild-
type tau transgene which is only expressed when the tetracycline transactivator transgene is also present. All experimental mice
were F1 crosses from two feeder lines to maintain a controlled outbred background strain with consistent proportions of B6,
B6C3, and FVB backgrounds. Parent strains used to generate the APP/PS1+Tau feeder lines were: (1) B6C3 APP/PS1mice express-
ing human APP with the Swedish mutation and human presenilin 1 with an exon 9 deletion under the control of the Thy1 promoter
(B6C3-Tg(APPsw,PSEN1dE9)85DboMmjax, Jax 34829) (Jankowsky et al., 2004); (2) MAPTnull mice which have the first exon of the
Mapt gene replaced with EGFP (Tucker et al., 2001); (3) mice expressing the tetracycline transactivator under the control of the cal-
cium calmodulin kinase 2 alpha promoter CK-tTA on the C57BL/6 backgrounds strain (B6.Cg-(Camk2a-tTA)1/MmayDboJ; Yasuda
and Mayford, 2006); (4) Tg21221 mice expressing human wild-type tau under a dox-off tetracycline transactivator promotor (FVB-
Tg(tetO-0N4R-MAPTwt)21221; Hoover et al., 2010). One feeder line was generated by crossing FVB.MAPTnull mice with the
FVB.Tg21221 mice to generate FVB Tg21221 MAPTnull mice homozygous for both the Tg21221 transgene and the MAPT knockout.
The other feeder line was generated by crossing B6C3 APP/PS1 mice with B6 MAPTnull mice to generate mice heterozygous for the
APP/PS1 transgene and homozygous for the MAPT knockout. These two feeder lines were bred to generate F1 experimental ani-
mals. Human tau is only expressed when the tetracycline transactivator is also expressed and can be suppressed by feeding the
mice doxycycline (Figure 1A). This consistent outbred background breeding scheme keeps variability low while avoiding potentiale2 Cell Reports 29, 3592–3604.e1–e5, December 10, 2019
pitfalls of inbred strains such as sensory deficits during aging, liver deficits, deletions such as loss of alpha-synuclein in some C57
strains, and other unknown recessive defects thatmay occur in inbred lines (Specht and Schoepfer, 2001; Cudalbu et al., 2013;Wong
and Brown, 2006). Out of the 395 mice born during the generation and phenotyping of the APP/PS1+Tau line, as expected 100%
were homozygous for endogenous tau knockout, 100% were heterozygous for the rTg21221 tau responder transgene, 53% were
heterozygous for the APP/PS1 transgene (50% expected), 48% were heterozygous for the CK-tTA activator transgene (50% ex-
pected), and 23% had both the APP/PS1 and CK-tTA transgenes (25% expected). 48% of the mice were female. Thus, the trans-
geneswere all inherited in the expectedMendelian ratios, indicating that no combination of genotypeswas lethal (Chi squared value =
6.41, p = 0.093, df = 3 confirmingMendelian ratios). This is an important advantage of our consistent outbred breeding scheme as the
same APP/PS1 transgene is lethal to about half of the mice on a congenic B6 background (Bennett et al., 2017). Genotyping of mice
was carried out on ear notch samples using PCR primer sequences found in Table S5.
One cohort of mice was aged and used for behavioral testing at 3, 6, and 9-10 months of age and sacrificed at 9-10 months of age
for pathological characterization (see Tables S1, S2, and S3 for all mouse data). Another cohort of mice was aged to 10-10.5 months
of age, tested for baseline behavior, then half of the mice were treated with 200ppm doxycycline in the chow for 4 months to reduce
tau transgene expression and the others treated with control chow (vehicle). Thesemice underwent behavioral testing again at at 14-
14.5 months of age then were sacrificed for pathological and molecular studies. Another cohort of littermates was aged to 6 months
and sacrificed to look at onset of pathology.
As a negative control to be sure that any effects of tau expression were not an artifact of the CKtTA activator transgene, which is
expressed in all mice that express tau by necessity, we examined B6.CKtTAmice on amouse tau null background at 9months of age
for behavioral and pathological changes. As a positive control for tau staining rTg4510 brain sections from 3 mice were used for tau
immunohistochemistry (Santacruz et al., 2005; Spires et al., 2006).
Behavioral testing
Group sizes for behavioral studies in the APP/PS1+Tau line can be found in figure legends and Table S1.We used distance traveled in
an open field to determine whether mice had a hyperactivity phenotype as has been used bymultiple groups previously as a proxy for
hyperactivity in AD model mice (see for example Blackmore et al., 2017; Yetman et al., 2016). Animals were tested for open field
behavior in a square box (40 3 40 3 60 cm) composed of dark opaque walls with approximately 2.5cm of corn cob bedding on
the floor of the arena. Animals were recorded using an overhead camera and the video signal fed into Blackmagic Media Express
computer software which captured the animals’ movements. Each day animals were brought into the testing room in their home
cage upon the end of the 12 hr dark cycle and allowed to settle for 1 hour. For habituation, animals were exposed to the open field
for 3 consecutive days. On day 1, animals were introduced to the center of the arena along with cage mates for 20 minutes. For days
2-4, individual animals were placed facing a corner of the arena, which was assigned using a random generator. For each experi-
mental group, the order in which animals were placed in the arena was randomly assigned using a random sequence generator.
On day 4, behavior in the open field was recorded for 10 minutes using an overhead camera and movements captured with Black-
magic Media Express software. idTracker software and MATLAB were used to analyze mouse behavior. The total distance traveled,
distance traveled in the outer segment (403 40 – inner segment), distance traveled in the inner segment (203 20), percentage of time
spent in the outer segment and percentage of time spent in the inner segment, were calculated and analyzed in SPSS and Prism7.
In order to ensure that the hyperactivity observed at 14.5 months of age is not a consequence of baseline performance prior to
treatment, 10.5 month old mice were assessed for baseline performance in the open field according to the treatment group to which
they would be assigned. A significant effect of genotype was observed (p < 0.0001), however there was no difference in open field
behavior in the cohorts destined for doxycycline or vehicle treatment within the same genotype (2-way ANOVA effect of treatment
F(1,164) = 0, p > 0.99999). This suggests the increase in total distance traveled in 14.5 month old vehicle-treated APP/PS1+Tau
mice and reversal with doxycycline is not due to baseline increased activity in this group at 10.5 months of age.
Measuring pathology
Mice were sacrificed by terminal anesthesia and perfused with PBS. Brains were dissected and one hemisphere fixed for 48 hours in
4% paraformaldehyde. Samples of entorhinal cortex from the other hemisphere were saved for array tomography as detailed below
and the rest of the hemisphere was frozen for biochemical analyses. The fixed hemisphere was cryoprotected in 15% glycerol and
sectioned into 50 micron coronal sections through the entire hemisphere with a sliding microtome (Leica SM2010R sliding micro-
tome). To quantify amyloid pathology, every 20th section was stained with a pan-Aß antibody and counterstained with 0.05% Thio-
flavine S in 50% ethanol to label plaque fibrils and any neurofibrillary tangles (antibody details are found in Table 2). Tile scan images
of each entire section were obtained with a 10x objective on a Zeiss Axioimager microscope. Images were analyzed using ImageJ.
The cortex and hippocampus on each section were outlined, regions of interest defined, and the area calculated. Cortical and hip-
pocampal volumes were estimated by multiplying the area on each section by 1000 (distance between sections), summing these
values for all sections, and multiplying by 2 to estimate total volume as we only measured one hemisphere. Each channel of amyloid
staining was manually thresholded in ImageJ by an experimenter blinded to genotype. The ImageJ analyze particles function was
used to calculate the percent area of cortex and hippocampus occupied by staining and the number and average size of individual
plaques. To calculate the burden of oligomeric halos surrounding plaques, the thresholded Thioflavin S image was subtracted from
the thresholded pan-Aß image and plaque burden, number, and size were analyzed as above.Cell Reports 29, 3592–3604.e1–e5, December 10, 2019 e3
Series of every 10th section were also stained with pathological tau antibodies to look for neurofibrillary tangles and neuropil
threads as detailed in Table 2. Stained sections were examined using a Zeiss AxioImager Z2 microscope and images acquired
with a CoolSnap digital camera. For tau stains, rTg4510mouse brain sections containing neurofibrillary pathology were used as pos-
itive controls.
Tomeasure gliosis burden, free floating coronal sections were stained for microglia (Iba1), astrocytes (GFAP), and fibrillary plaques
(Thioflavine S), with citrate buffer pre-treatment (95C for 20 minutes, see Table 2 for antibody details). Three coronal sections were
stained per mouse at approximately 0.75mm, 2.0mm, and 3.75mm from Bregma. Tile scans were obtained at 10x magnification
using a ZEISS Imager.Z2 microscope and images were thresholded on ImageJ for cortical burden quantification. For all immunos-
tains, no primary conditions were used as negative controls.
To examine synaptic proteins within microglia, 2 coronal sections per mouse (Bregma 1.0 and 3.0, n = 5 mice per group) were
stained formicroglia (Iba1), synaptophysin (SY38), DAPI, and fibrillar plaques (Thioflavine S 0.05% in 50%ethanol). Citrate buffer pre-
treatment was used for antigen retrieval (95C for 20 minutes, see Table 2 for antibody details). Confocal image stacks were acquired
on a Leica TCS SP8 confocal with z-step of 1 micron. Z stack reconstructions were performed in ImageJ and Imaris to confirm syn-
aptic proteins within Iba1 positive cells.
RNA analyses
Total RNA was extracted from the frontal cortex using the Lipid Tissue Mini Kit (QIAGEN). RNA quantity and quality was assessed
using a Bioanalyzer 2100 (Agilent Technologies). All samples had RIN values > 7. To generate RNA-seq data, barcoded RNA-seq
libraries were prepared by Edinburgh Genomics using the Illumina TruSeq stranded mRNA-seq kit, according to the manufacturer’s
protocol (Illumina). The libraries were pooled and sequenced using an Illumina Novaseq 6000. RNA-sequencing was performed to a
depth of 60 million 50bp paired-end reads per sample. Reads were mapped to the mouse primary genome assembly (GRCm38)
contained in Ensembl release 92 (Zerbino et al., 2018). Read alignment was performed with STAR (Dobin et al., 2013), version 2.5.3a,
and tables of per-gene read counts were generated from the mapped reads with featureCounts (Liao et al., 2014), version 1.5.2. Dif-
ferential expression analysis was then performed using DESeq2 (R package version 1.18.1) (Love et al., 2014). GeneOntology enrich-
ment analysis was performed with topGO [5] (R package version 2.30.1), and pathway analyses were performed with Ingenuity
Pathway Analysis software (Kra¨mer et al., 2014). An adjusted p value cut-off of < 0.05 was set to identify molecules whose expression
was differentially regulated.
For qRT-PCR, cDNA was synthesized using the SuperScript VILO cDNA synthesis kit (ThermoFisher) and the following PCR set-
tings used: 10minutes at 25C, 60minutes at 42C and 5minutes at 85C. qPCRs were run on a StratageneMx3000PQPCR System
(Agilent Technologies) using SYBR Green MasterRox (Roche) with 6 ng of cDNA per well of a 96-well plate, using the following pro-
gram: 10 min at 95 C, 40 cycles of 30 s at 95 C, 40 s at 60 C and 30 s at 72 C, with a subsequent cycle of 1 min at 95 C and 30 s
at 55 C ramping up to 95 C over 30 s (to measure the dissociation curve). Primers used are found in Table S5.
Array Tomography
Fresh brain tissue samples were collected from 14.5 month old mice and human subjects as outlined previously (Koffie et al., 2009;
Kay et al., 2013). Small tissue blocks containing cortex were fixed in 4% paraformaldehyde and 2.5% sucrose in 20 mM phosphate
buffered saline pH 7.4 (PBS) for 3 hours. Samples were then dehydrated through ascending cold graded ethanol and embedded into
LRWhite resin (EMS) which was allowed to polymerize overnight at 53C. Resin embedded tissue blocks were cut into array ribbons
of 70 nm thick sections using an ultracut microtome (Leica) equipped with a Jumbo Histo Diamond Knife (Diatome, Hatfield, PA) and
collected onto gelatin coated coverslips.
For pathological protein colocalization with postsynapses, array ribbons were immunostained with primary antibodies against post
synapses (PSD95), oligomeric Ab (1C22) and total tau (pan-tau). For pathological protein colocalization with pre-synapses, array rib-
bons were immunostained with primary antibodies against synaptic vesicle protein synaptophysin, Ab (AW7) and total tau (pan-tau)
(Table 2). Sections were counterstained with 0.01 mg/mL 4’-6-diamidino-2-phenylindole (DAPI). In each experiment, a short extra
ribbon was used as a no primary negative control. Images were obtained on serial sections using a Zeiss axio Imager Z2 epifluor-
escent microscope with a 10x objective for tile scans and 63x 1.4NA Plan Apochromat objective for high resolution images. Images
were acquired with a CoolSnap digital camera and AxioImager software with array tomography macros (Carl Zeiss, Ltd, Cambridge
UK).
Human brain array tomography ribbons were stained with combinations of synaptic antibodies, tau antibodies and AW7 to label
amyloid beta as described in the Figs and Table 2. For two-day stains, antibodies applied for the first imaging day were stripped by
incubation in aqueous 0.02%SDS and 0.8% sodium hydroxide solution for 20minutes. Stripped ribbons were rinsed in water and re-
probed with another set of primary then secondary antibodies.
Images from each set of serial sections were converted into image stacks and aligned using the ImageJ plug-in, MultiStackReg
(courtesy of Brad Busse and P. Thevenaz, Stanford University) (The´venaz et al., 1998). Regions of interest within the cortical
neuropil were chosen (10 mm2) and their proximity to plaque edges recorded (< 20 mm from a plaque edge considered ‘‘near’’ plaques
and > 20 mm from a plaque edge considered ‘‘far’’ from plaques). Image stacks were then binarised using thresholding algorithms in
ImageJ. For synaptic staining, images stacks were binarised using an ImageJ script that combines different thresholding algorithms
in order to select both high and low intensity synapses in an automated and unbiased manner. To calculate the synaptic density,e4 Cell Reports 29, 3592–3604.e1–e5, December 10, 2019
thresholded images were processed and analyzed in MATLAB to remove background noise (objects present in only a single section
were removed). To examine pathological protein presence at the synapse, thresholded images were processed and analyzed in
MATLAB to remove background noise and to calculate the colocalization of total tau and oligomeric Ab with post synapses individ-
ually and in combination (a minimum of 50% of the synapse volume had to overlap with tau and/or 1C22 to qualify as positive for that
stain).
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were carried out by a person blind to genotype and treatment of the mice and blind to diagnosis for human studies.
For each experimental variable, a percentage, mean or median was calculated for each subject (experimental unit was the mouse or
human case). Groups of mice or people were compared with parametric or non-parametric tests as appropriate based on the
normality of the datasets as assessed by Shapiro-Wilks tests. Statistical tests were carried out in SPSS and Prism7. The number
of subjects and statistical tests used for each experiment are indicated in the results, Fig legends, and data analyzed is found in
Tables S1 and S2 (mouse) and S4 (human).
DATA AND CODE AVAILABILITY
Spreadsheets of all data used in this study are included as Tables S1, S2, S3, and S4. The accession number for the RNA-seq data
generated reported in this paper is European Bioinformatics Institute depository ArrayExpress: E-MTAB-7856 (https://www.ebi.ac.
uk/arrayexpress/experiments/E-MTAB-7856/). Custom imageJ and MATLAB macros used for image analysis are freely available on
the University of Edinburgh Data Sharing repository (https://datashare.is.ed.ac.uk/handle/10283/3380).Cell Reports 29, 3592–3604.e1–e5, December 10, 2019 e5
